Drug intelligence / Profile preview

Valiflore

Development stage
Unknown
Lead developer
Niak Pharmaceutical Company
Administration
Oral
01

Overview

Valiflore is an over-the-counter (OTC) herbal combination product developed and manufactured by Niak Pharmaceutical. Formulated as an oral tablet, each dose contains 100 mg of valerian (*Valeriana officinalis*) root extract and 30 mg of passionflower (*Passiflora incarnata*) extract. Valiflore is primarily indicated for the treatment of anxiety, stress, restlessness, and sleep disorders (insomnia) associated with nervous tension. It is also utilized to alleviate gastrointestinal and neuromuscular spasms of nervous origin. The active constituents, including valerenic acid from valerian and flavonoids (such as vitexin) from passionflower, exert synergistic sedative and anxiolytic effects by modulating the gamma-aminobutyric acid (GABA) system. Specifically, they increase synaptic GABA concentrations by inhibiting its reuptake and enzymatic degradation (via GABA transaminase inhibition) and by acting as positive allosteric modulators at GABA-A receptors.

Brand names
Valiflore
Other names
Niak ValifloreValiflore Tablet
02

Targets

GABRR (GABA-A receptor subunit rho)BZD site (GABA-A receptor benzodiazepine site)ABAT (4-aminobutyrate aminotransferase)

Beyond the preview

Go deeper on Valiflore.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Valiflore.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call